Change in Orion Group Executive Management Board as of 21 February 2017
(Thomson Reuters ONE) -
ORION CORPORATION STOCK EXCHANGE RELEASE 13 FEBRUARY 2017 at 9.00 a.m.
EET
Change in Orion Group Executive Management Board as of 21 February 2017
Dr. Reijo Salonen, M.D., Ph.D., Senior Vice President for Research and
Development of the Orion Group and member of the Executive Management Board of
the Orion Group will, according to his employment contract, retire as of 1 July
2017. He will step aside from his current positions (incl. also the membership
in the Executive Management Board of the Orion Group) as of 21 February 2017 and
has been appointed to the position of Senior Advisor until the end of his
employment, reporting still to the President and CEO of Orion Corporation.
Dr. Christer Nordstedt, M.D., Ph.D., has been appointed Senior Vice President
for Research and Development and member of the Executive Management Board of the
Orion Group, as of 21 February 2017. Nordstedt joins Orion from Eli Lilly, USA,
where his latest position was Vice President and Head CNS Research and Clinical
Investigation. Nordstedt has worked at Eli Lilly since 2011. Before that time he
worked for many years in various leadership positions in Research and
Development at Roche in Switzerland and at AstraZeneca in Sweden. Prior to his
career in the pharmaceutical industry, Nordstedt held the position of Laboratory
Head at the Karolinska Institute in Stockholm, Sweden. Prior to that, Nordstedt
worked in the laboratory of Dr. Paul Greengard (Nobel Laureate 2000) at the
Rockefeller University in New York, USA. Nordstedt, born in 1962, is a citizen
of Sweden.
Timo Lappalainen, President and CEO, says:
"With Reijo Salonen's leadership for the past 10 years, Orion's Research and
Development operations have developed into a recognized world-class organization
with a strong clinical pipeline and numerous global partnerships. It is my
pleasure to thank Reijo for his long lasting and distinguished career as the
leader for Orion's Research and Development operations. Reijo's successor,
Christer Nordstedt, has held many senior positions in Research and Development
in the international pharmaceutical industry. I am confident that with
Christer's leadership Orion will continue to develop both clinically relevant
new pharmaceutical products and high quality generic products to address the
cost containment objectives of payors. I warmly welcome Christer to Orion and as
member of Orion's Executive Management Board."
The CV of Christer Nordstedt is attached.
Picture of Christer Nordstedt
(http://www.orion.fi/globalassets/pictures/christer_nordstedt.jpg)
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO Senior Vice President,
Corporate Functions
Contact person:
Timo Lappalainen, President and CEO, phone +358 50 966 3692
Appendix: The CV of Christer Nordstedt
APPENDIX
The CV of Christer Nordstedt
Christer Nordstedt
Ph.D, Karolinska Institute, Sweden 1991
M.D., Karolinska Institute, Sweden 1989
b. 1962
Senior Vice President, Research and Development as of 21 February 2017
Career
2011-2017 Vice President and Head CNS Research and Clinical Investigation,
Eli Lilly Research Laboratory, USA
2007-2011 Global Head and SVP, CNS Discovery, F. Hoffmann-La Roche,
Switzerland
2000-2007 Vice President Discovery & Preclinical Development CNS/Pain
Control, Site Head Mölndal, AstraZeneca, Sweden
1997-2000 Various leadership positions in Research and Development, F.
Hoffmann-La Roche, Switzerland
1992-1998 Laboratory Head, Clinical Neurobiology, Karolinska Institute,
Sweden
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish pharmaceutical company - a builder of
well-being. Orion develops, manufactures and markets human and veterinary
pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The
company is continuously developing new drugs and treatment methods. The core
therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS)
disorders, oncology and respiratory for which Orion developes inhaled Easyhaler®
pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and
the company had about 3,500 employees. Orion's A and B shares are listed on
Nasdaq Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in
2017.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Naturally Splendid Highlights HempOmega™ Dog Food StudyDatum: 13.02.2017 - 08:00 Uhr
Sprache: Deutsch
News-ID 523612
Anzahl Zeichen: 5486
contact information:
Town:
Espoo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 297 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Change in Orion Group Executive Management Board as of 21 February 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
